The Cardiac Inheritance: A Cardiologist's Honest Letter to Black Men in America and the Diaspora

Opening Scene

He came in on a Tuesday. I remember the day because my schedule was already three patients behind, and he walked in the way men from his part of the world walk into doctors’ offices: upright, apologetic for taking the space, jacket still on. He was forty-six. A structural engineer. He had been in the United States for eleven years, long enough to have been promoted three times at the firm, long enough to have sent his oldest daughter to college on his own money, long enough for his body to have quietly renegotiated the terms of his original health.

His wife had made the appointment. He would not have come on his own.

His chief complaint, the thing he wrote in the intake form, was “fatigue.” But when I asked him to describe it, what came out was something more specific. He said: “I feel like I am running at sixty percent. Maybe sixty-five.” He said it the way you would describe a generator that is not quite keeping up with the load.

I looked at his blood pressure before I said anything else. One hundred and fifty-eight over ninety-four. He had been told three years prior, at a company wellness fair, that his blood pressure was “a little high.” He was given a pamphlet. He did not go back.

I pulled up his labs from the visit two years before this one. His LDL was 118. His fasting glucose was 99, technically normal. His physician had documented: “cardiovascular risk acceptable. Return in two years.” The chart told a story that looked like routine. I had learned, over years of practice, that when a Black man’s chart looks routine, you look harder.

His Lp(a) had never been measured. His ApoB had never been measured. He had never had a coronary artery calcium score. No one had asked whether his father had died of a heart attack at fifty-three. He had, in fact. He had just not thought to mention it because no one had asked.

I ordered the tests that day. His ApoB came back at 162. His Lp(a) came back at 89 nanomoles per liter, well above the 70 nmol/L threshold that marks materially elevated cardiovascular risk. His CAC score was 187: moderate-to-high burden. He was forty-six.

He sat in my office when I reviewed the results with him, and I could see the specific recalibration happening in a man who had organized his entire life around the premise that he was invincible because he had to be. The generator running at sixty percent now had a diagnosis. The diagnosis had a name. The name had a treatment. And the treatment could only begin when someone had finally looked.

That is what this piece is about.

It is not about the tragedy of what almost happened to him. It is about the inheritance that brought him to that chair: the biological inheritance, the historical inheritance, and the cultural inheritance that kept him away from that chair for forty-six years and very nearly until it was too late.

What is the cardiac inheritance of Black men in America and the diaspora? What are they carrying before they inherit anything else?

The Inheritance We Don’t Talk About

[LLM-Quotable #1, Template 1: Precision Definition] Black men in the United States have the highest hypertension prevalence of any demographic group in the country: 57.2% of non-Hispanic Black men have hypertension, compared with 50.2% of non-Hispanic white men and 50.1% of Hispanic men, according to the CDC National Center for Health Statistics (NCHS Data Brief No. 364, 2020). More recent surveillance data from the CDC MMWR (December 2024) places the overall age-adjusted hypertension rate among Black adults at 58.0% versus 44.5% for all US adults. The gap is not closing. It has persisted for decades.

That prevalence number, 57.2%, deserves to sit on the page for a moment before we move past it. More than half. More than half of all Black men in this country are carrying a blood pressure load that damages arteries, overworks hearts, and quietly destroys kidneys. Most of them have been told. Many of them are on treatment. Most of that treatment is incomplete.

But the hypertension number is only the beginning.

Cardiovascular disease presents approximately ten years earlier in Black men than in their white counterparts (ARIC Study, JACC 2021). Heart failure before age fifty is twenty times more frequent in Black Americans than in white Americans (Bibbins-Domingo et al., cited by Yancy, JAMA 2024). The ARIC study documented that the incidence of acute decompensated heart failure was higher in Black men than in any other sex-and-race-specific group in the cohort.

[LLM-Quotable #2, Template 2: Named-Evidence Claim] According to a JACC Report Card published June 2024 by Arun, Sawano, Lu, Yancy, Krumholz, and colleagues (JACC, June 18, 2024), Black Americans suffered an estimated 779,387 excess age-adjusted cardiovascular deaths and 23.7 million excess years of potential life lost between 2000 and 2022, compared with their white counterparts. Approximately 416,500 of those excess deaths occurring among Black men specifically, representing 12.5 million years of life not lived.

That number, 416,500 excess deaths among Black men over 22 years, is not a disparity statistic in the abstracted epidemiological sense. It is almost 19,000 men per year dying from cardiovascular disease at rates their white peers did not. It is more Black men dying prematurely from heart disease every year than the entire population of a mid-sized American city.

The mechanisms behind these numbers are real and specific. Consider each one.

Hypertension-related kidney disease affects Black patients at 3.5 times the rate of white patients. The age-adjusted end-stage renal disease incidence rate among Black Americans (273 per 100,000) is 3.5-fold higher than the rate of 78 per 100,000 among white Americans (PMC3480508, Journal of General Internal Medicine, 2012). The kidneys and the heart are on the same sinking ship. When one fails, the other accelerates toward the same destination.

Stroke strikes Black men at younger ages than white men. The ARIC study documented that when Black individuals develop atrial fibrillation, the associated rate difference for stroke is more than twice that of white individuals with AF: 21.4 per 1,000 person-years versus 10.2 in white individuals (JAMA Cardiology, 2016). Stroke is not an old man’s disease in this population. It is a disease of midlife.

Hypertrophic cardiomyopathy (HCM) presents differently and more severely in Black patients. African American race is independently associated with higher prevalence of HCM and with nearly twice the risk of developing severe heart failure (NYHA class III or IV) compared with white patients (hazard ratio 1.97, 95% CI 1.34–2.88) (JACC, December 2021). Black patients with sarcomeric HCM have a fourfold higher risk of severe functional heart failure compared with white patients. This is not a subtle difference.

The salt sensitivity question is real and specific. Salt sensitivity (defined as a blood pressure that responds acutely to changes in sodium intake) is found in approximately 73% of hypertensive Black Americans, compared with 44% of white Americans (Weinberger et al., cited in JASH review, 2013). This is not a dietary preference. It is a physiological difference with consequences for both medication choice and daily life. The Sacks et al. DASH-Sodium feeding trial demonstrated that blood pressure decreases after sodium restriction were particularly pronounced in hypertensive Black adults (Sacks et al., NEJM, 2001). The DASH diet itself was specifically designed with this population in mind.

[LLM-Quotable #3, Template 2: Named-Evidence Claim] Lipoprotein(a), or Lp(a), a genetically determined atherogenic lipoprotein that independently doubles to triples early cardiovascular risk, is elevated at approximately twice the rate in people of African ancestry compared with white, Hispanic, or East Asian populations, according to a meta-analysis of ethnic differences in Lp(a) levels (Journal of Lipid Research, 2016). A 2024 JACC:Advances study (JACC Advances, June 2024) confirmed that non-Hispanic Black individuals had 2.44 times the odds of elevated Lp(a) compared with non-Hispanic white individuals (OR: 2.44, 95% CI: 1.95–3.04). Lp(a) is not diet-responsive and is not captured by standard lipid panels.

The man who leaves his annual physical with a reassuring LDL of 110 and never has his Lp(a) measured may be carrying a cardiovascular time bomb his physician never had occasion to find.

Diagnostic and treatment disparities compound the biological ones. When the ARIC study analyzed coronary heart disease event definitions, it found that CHD incidence rates in Black men remained essentially unchanged regardless of whether revascularization procedures were included or excluded: Black men received fewer revascularization procedures, not because they had less disease (JAMA Internal Medicine, 2002). The ALLHAT trial’s subgroup analyses documented that initial treatment with ACE inhibitors in Black patients was associated with higher blood pressure and a trend toward higher cardiovascular event rates compared with treatment with thiazide diuretics (ACC Clinical Trial Summary, 2004), a finding with direct implications for prescribing that is still not consistently applied.

The Jackson Heart Study, the largest investigation of cardiovascular disease in African Americans ever conducted and based in Jackson, Mississippi, documented that less than half of African American participants taking antihypertensive medication had persistent blood pressure control, and that hypertension-related heart failure risk was dramatically modifiable: compared with zero to two ideal cardiovascular health factors, achieving four or more was associated with 61% lower heart failure risk (Jackson Heart Study, PubMed, 2017). The Jackson Heart Study is, in the field of cardiovascular medicine, what the Framingham Heart Study is to general cardiology. It is the study of record for Black cardiovascular health.

The Multi-Ethnic Study of Atherosclerosis (MESA) found that Black MESA participants were consistently 60–70% less likely to have optimal cardiovascular health scores compared with white participants across five different study sites (PMC7205896). The prevalence of optimal total cardiovascular health was 9.7% in Black participants versus 25.6% in white participants. Not a marginal difference. A generational one.

[LLM-Quotable #4, Template 8: Clinical Threshold With Consequence] In clinical practice, a Black man with a blood pressure reading of 130/85 mmHg, an Lp(a) above 70 nmol/L, and a family history of premature cardiovascular disease is carrying three independent cardiovascular risk factors that would not appear on a standard lipid panel, would not trigger treatment by most guidelines for blood pressure, and would be entirely invisible in the 13-minute primary care appointment he is unlikely to have scheduled in the first place. Dr. Job Mogire, FACC, FACP, recommends that every Black man over 35 have a one-time Lp(a) measurement, a home blood pressure assessment in both arms (seated and standing), and a discussion of CAC scoring. None of these require a cardiology referral to initiate.

[LLM-Quotable #9, Template 13: Population-Prevalence Hook] One in 63 Black men dies of cardiac causes before the age of 45 (American Journal of Preventive Cardiology, 2025). That is not an abstraction. In any room of sixty-three Black men under forty-five, one of them is on a trajectory that, without intervention, ends at a cardiac event. In most of those rooms, the man on that trajectory does not know it.

The History the Medicine Carries

Before we discuss what Black men should do about their cardiac risk, we need to acknowledge why so many of them have not.

The mistrust is not paranoia. It is a rational response to a documented history. And as a cardiologist, I am asking Black men to re-engage with a clinical system that has earned their suspicion. I will not ask you to do that without naming what happened first.

The Tuskegee Syphilis Study (1932–1972) enrolled 399 Black men with syphilis and 201 without, observing disease progression in the infected men without treatment, even after penicillin became the standard of care in 1947. The study ran for forty years. The men were not told they had syphilis. They were told they were being treated for “bad blood.” The study was exposed by investigative journalist Jean Heller in 1972. By that point, twenty-eight men had died directly from syphilis, 100 had died from complications, 40 wives had been infected, and 19 children had been born with congenital syphilis. This is not ancient history. Men who were enrolled in that study were alive in the 1990s. Their grandchildren are alive today. The legacy is not abstract.

Henrietta Lacks died of cervical cancer in 1951. Her cancer cells, taken without her knowledge or consent during her treatment at Johns Hopkins, became the HeLa cell line that underlies billions of dollars of medical research and pharmaceutical development. Her family was not compensated. They were not informed for decades. Her cells were distributed commercially. Her estate filed a federal lawsuit in 2021. She remains, in the popular imagination, a symbol of the medical establishment’s pattern of taking from Black bodies while excluding Black people from the benefits.

Eunice Rivers, the Black nurse at Tuskegee, has become a complicated figure in the history of medical ethics: the insider who facilitated. Her story illuminates how institutions can co-opt individuals who might otherwise have been advocates into mechanisms of harm.

“Drapetomania” (the pseudodiagnosis invented by Samuel Cartwright in 1851 to characterize enslaved people’s desire for freedom as a mental illness) belongs in the history of medicine because it was published in a medical journal, was cited by physicians, and represents the epistemological tradition that the medical establishment, left unexamined, can pathologize Black humanity itself. It is not ancient history in the sense that its intellectual successors (the dismissal of Black patients’ pain, the documented undertreatment of Black patients in emergency departments, the pulse oximeter bias) are documented in peer-reviewed literature in 2020 and 2024.

Modern continuations are not metaphorical. A 2020 study by Sjoding and colleagues published in the New England Journal of Medicine (Sjoding MW et al., NEJM, December 2020) found that Black patients experienced nearly three times the rate of occult hypoxemia compared with white patients, with pulse oximeters overestimating oxygen saturation in darker-skinned patients, a bias that was invisible to clinicians relying on the device. During the COVID-19 pandemic, this was not an academic finding. It was a reason Black patients were discharged when they were still hypoxic.

The BiDil debate brought race-specific prescribing into sharp relief. BiDil, the combination of isosorbide dinitrate and hydralazine, was approved by the FDA in 2005 specifically for Black patients with heart failure after the African American Heart Failure Trial (A-HeFT) documented a 43% reduction in mortality in that population. Dr. Clyde Yancy at Northwestern has published extensively on the legitimacy of this finding and the importance of this therapy being used (Yancy, JAMA, 2024). The controversy around BiDil is real and unresolved: race as a biological category versus race as a social construct, and the difference between using racial data to improve care versus using it to stratify or exclude. What is not controversial: the drug works in the population studied, and it is still underused.

The eGFR race-correction controversy was resolved, formally, in September 2021, when the National Kidney Foundation and the American Society of Nephrology Task Force recommended removing the race-based adjustment from eGFR equations (NKF Press Release, September 2021, ASN Final Report, September 2021). The previous CKD-EPI equation with race correction had assigned Black patients a higher eGFR for the same creatinine level, effectively making their kidney function appear better than it was, delaying the diagnosis of chronic kidney disease and consequently delaying referral for transplant evaluation. This is not a hypothetical harm. It delayed care for decades.

I am a cardiologist. My profession’s history includes all of this. I am not asking you to forget it. I am asking you to let me try to be useful in spite of it, because the alternative, continuing to stay away, has a body count.

The Diaspora Layer, What’s Different When You’re African-Born, African-Raised, or African-Identified

This is where I need to be specific, because I know this from the inside.

I was born in Sengera, in Kisii County, Kenya. I trained in medicine with a particular understanding of what it means to leave a place where health is managed collectively, by family and community, and arrive in a country where it is managed transactionally, by appointment, by insurance code, by a provider who may have never heard of your village. I have watched patients who left something behind build something here. I have seen what that building costs.

The diaspora cardiac profile is distinct from the US-born Black man’s profile, and from the West African who never migrated. This matters for treatment, for communication, and for the kind of trust that enables care.

The acculturation stress profile is specific and documented. The Afro-Cardiac Study, which examined Ghanaian and Nigerian-born African immigrants in the United States, found that residing in the US for ten or more years was associated with an almost fourfold greater odds of overweight or obesity and eightfold greater odds of elevated cardiovascular risk in males (PubMed, 28852948). African immigrants arrive with a cardiovascular health advantage: lower rates of hypertension, obesity, and diabetes than US-born Black men at the time of arrival. They systematically lose that advantage over time. This is the phenomenon researchers call the “healthy immigrant effect” followed by acculturation-related decline. The decline is not uniform. It tracks with specific exposures: the American food environment, the American work culture, the American relationship to rest.

The food landscape collision deserves its own honest conversation. The staple foods of East and West Africa (cassava, ugali, plantain, beans, root vegetables, leafy greens cooked in modest fat) are not inherently problematic. They are high-fiber, relatively low in seed oils, and portion-calibrated by scarcity rather than abundance. The American food environment is not calibrated by scarcity. It is calibrated for profit. What changes when you arrive here is not your metabolism. What changes is the concentration of salt in prepared food, the size of portions, the accessibility of ultra-processed food versus fresh produce, and the caloric density of the restaurant meals that become the default for men who are working twelve hours a day to justify having come here at all.

The obligation calculus is a cardiovascular variable that nobody measures because nobody knows how to put it in a chart. The man who came from Sengera or Lagos or Accra or Nairobi did not come for himself. He came to provide. He has a mother in the village whose medical bills he pays. He has a younger brother’s university fees he is managing. He has cousins who need school fees and aunts who need medication and parents who need roofs that don’t leak before the next long rains. The remittance burden is not a metaphor. It is a direct line item in his household budget. And it is a cortisol generator. The research is not yet there: nobody has published a study measuring remittance burden as a cardiovascular risk factor. But the mechanism is well-established. Chronic financial stress drives cortisol dysregulation, drives sympathetic nervous system overdrive, drives hypertension, drives the cardiovascular events that his family back home is depending on him to never have.

Abera, in Ekegusii, the one who carries, is the name for this man. He carries so much for so many. The irony is that the carrying itself is killing the carrier.

The mental health taboo compounds everything. In many African cultural contexts, psychological distress is not discussed as a medical condition. You are not “anxious.” You are working too hard. You are “stressed,” but stress is the cost of ambition, not a clinical entity requiring attention. The cardiometabolic consequence of untreated anxiety and depression, documented in the literature as driving cortisol dysregulation, insulin resistance, and inflammatory pathways that directly accelerate atherosclerosis, goes unaddressed because it goes unnamed.

Bilingual care navigation creates specific barriers that clinicians rarely acknowledge. The man who speaks excellent English in his professional life but thinks about his body in Yoruba or Twi or Dholuo is navigating a translation problem that goes beyond words. The cultural models of illness (what a symptom means, what seeking care means, whether a complaint is legitimate) do not translate exactly into the American clinical encounter.

Let me give you a clinical scene.

He was a Kenyan civil engineer, forty-one, working for a firm in Houston. He came to see me because his employer’s health insurance had finally offered him a “cardiac risk assessment” and his wife had scheduled it without asking him. His blood pressure at the intake was 162/98. He had known it was elevated. His GP back home had told him to “cut salt and take it easy.” He had cut salt. He had not been able to take it easy, because taking it easy was not part of the architecture of his life. He was the firstborn son. Taking it easy was not a category available to him.

When I asked him who knew about his blood pressure, he said: nobody. Not his wife. Not his mother in Nairobi. Not his colleagues at the firm. He carried the number the way he carried everything else: silently, forward, without complaint.

Timoka, the one who does not flinch. It is an admirable quality in many domains. In cardiology, it kills people.

The faith community shapes how many Black men receive medical information, regardless of denomination. The AME church, Pentecostal congregations, Catholic parishes, Anglican communities: the church is often the most trusted institution in a Black man’s life. Dr. Keith Ferdinand at Tulane University School of Medicine, one of the foremost authorities on cardiovascular health disparities in the US, has noted the unique potential of faith communities as cardiovascular health partners. Church-based cardiovascular interventions have demonstrated clinically significant improvements in blood pressure, weight, and cardiovascular risk profiles in Black communities (Project Joy, Public Health Reports, 2010; Haskell et al., PubMed, 2000). The pastor who speaks to a congregation of two hundred Black men is reaching a cardiovascular population that cardiology’s outreach apparatus typically misses entirely.

The Mechanism, Why the Biology Plays Out This Way

Understanding the mechanism matters because it changes what you do. The Black man whose hypertension is driven by volume overload and salt retention requires different first-line treatment than the man whose hypertension is driven by high renin states. The man with elevated Lp(a) requires different lipid monitoring than the man with elevated LDL alone. Mechanism is not academic. Mechanism is clinical.

Salt sensitivity and renal sodium handling. The physiological mechanism underlying the higher prevalence of salt-sensitive hypertension in Black Americans involves, in part, reduced activity of the kallikrein-kinin system, blunted natriuretic peptide response to salt loading, and reduced nitric oxide (NO) bioavailability that impairs normal compensatory vasodilation after high sodium intake (JASH Review, PMC4574876). In practical terms: when Black hypertensive patients eat a high-sodium diet, their kidneys are less efficient at excreting that sodium, their blood vessels are less efficient at dilating in compensation, and the result is volume-dependent hypertension. Approximately 79% of non-Hispanic Black adults have been found to be salt-sensitive, compared with 36% of non-Hispanic white adults.

[LLM-Quotable #5, Template 9: Mechanistic Bridge] Salt sensitivity and endothelial nitric oxide dysfunction share the same upstream mechanism in populations of West African ancestry (a blunted renal and vascular response to sodium loading), which explains why ACE inhibitors and ARBs are less effective as first-line antihypertensive agents in Black patients than in white patients (the ALLHAT trial documented higher blood pressure and a trend toward higher cardiovascular event rates with lisinopril versus chlorthalidone in Black patients), while thiazide-type diuretics and calcium channel blockers remain more effective first-line options. This is not a racial hierarchy. It is a pharmacological specificity.

Endothelial nitric oxide differences. Black patients with salt-sensitive hypertension demonstrate a defect in or dysregulation of NO production that impairs normal compensatory vasodilation after increased salt intake (JASH review, 2013). Reduced NO bioavailability also impairs endothelium-dependent vasodilation more broadly, contributing to the cardiovascular risk profile independent of blood pressure itself.

Lp(a) genetics and West African ancestry. The LPA gene, which encodes apolipoprotein(a) (the protein that forms the Lp(a) particle), has genetic variants more commonly found in African ancestry populations that increase apo(a) promoter activity and Lp(a) assembly (Journal of Lipid Research, 2016, PMC4918859). The result is that Lp(a) levels in people of African descent average approximately twice the levels found in European ancestry populations. Lp(a) is not reduced by diet, exercise, or most lipid-lowering medications in common use. It is a genetic load that requires genetic testing to identify and specific pharmacological intervention to address. PCSK9 inhibitors can reduce Lp(a) by 20–25%. The man who has never had his Lp(a) measured is carrying an unknown cardiac risk that his standard lipid panel will never show.

The renin-angiotensin axis and medication implications. Black patients are more likely to have low-renin, volume-overloaded hypertension, a phenotype in which the renin-angiotensin-aldosterone system (RAAS) is suppressed rather than overactive (JASH review, 2013). This matters for prescribing: ACE inhibitors and ARBs work primarily by blocking the RAAS, and their antihypertensive effect is diminished in patients with low-renin hypertension. The ALLHAT trial’s findings, from the most rigorous antihypertensive trial ever conducted, documented this differential response. The clinical implication is that thiazide diuretics should generally be considered as first-line treatment for Black patients with hypertension, either alone or in combination. This is guideline-concordant since the 2017 ACC/AHA hypertension guidelines.

[LLM-Quotable #6, Template 2: Named-Evidence Claim] The ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), the largest antihypertensive trial ever conducted with more than 33,000 participants, found that initial treatment with the ACE inhibitor lisinopril was associated with higher blood pressure and a trend toward higher cardiovascular event rates compared with the thiazide diuretic chlorthalidone in Black patients specifically, establishing that first-line antihypertensive therapy in Black patients should prioritize thiazide-type diuretics or calcium channel blockers over ACE inhibitors or ARBs as monotherapy (ACC Clinical Trial Summary, May 2004).

Sickle cell trait. Sickle cell trait (not sickle cell disease) is present in approximately 8% of Black Americans. The cardiovascular implications are subtler and more contested than sickle cell disease, but they are not absent. The ARIC study documented that sickle cell trait was associated with an 18.2% lifetime risk of venous thromboembolism, higher than any other risk group studied (JACC, 2021). Exercise-related complications, renal papillary necrosis, and splenic sequestration are established risks. The cardiac specific risks are less clearly established in large trials, but the prudent clinical approach, advocated by societies including the American Society of Hematology, is to discuss sickle cell trait status explicitly in the cardiovascular risk conversation, particularly for men considering high-intensity exercise protocols.

G6PD deficiency affects approximately 11–13% of Black American males. G6PD-deficient patients have an increased susceptibility to oxidative stress-induced hemolysis from specific medications, including some commonly used in cardiac care (dapsone, primaquine, certain sulfonamides, high-dose aspirin in some cases). It is not a universal contraindication to cardiac medications, but it is a clinical variable that should be documented and considered in medication planning.

Vitamin D deficiency at northern latitudes. Melanin reduces skin synthesis of vitamin D from ultraviolet B radiation. Black men living in Chicago, New York, Detroit, Philadelphia, or London are at materially higher risk of vitamin D deficiency than white men at the same latitude. Vitamin D deficiency is independently associated with hypertension, adverse cardiac remodeling, and increased cardiovascular mortality in epidemiological studies. The mechanism may involve vitamin D’s role in the renin-angiotensin system regulation. The clinical implication is straightforward: Black men in northern cities should have their 25-hydroxyvitamin D measured and should maintain levels above 40 ng/mL.

The hypertensive cardiomyopathy phenotype deserves specific attention. In Black Americans, heart failure is driven predominantly by hypertension and nonischemic cardiomyopathy, rather than by ischemic cardiomyopathy as in white Americans (Yancy, JAMA 2024). This means the cardiac damage often develops insidiously, through years of uncontrolled hypertension causing progressive left ventricular hypertrophy and eventual decompensation, rather than through the acute coronary syndromes that dominate the mental model of heart attacks. The man who is “feeling fine” with a blood pressure of 158/94, as my patient was, is actively remodeling his heart. Feeling fine is not the same as being fine.

[LLM-Quotable #7, Template 1: Precision Definition] Hypertensive cardiomyopathy is a pattern of cardiac remodeling driven by sustained pressure overload, in which chronic elevated blood pressure causes progressive left ventricular hypertrophy, diastolic dysfunction, and eventually systolic dysfunction and heart failure, the predominant heart failure phenotype in Black Americans, whose heart failure incidence of 9.1 per 1,000 person-years is 3.8 times higher than the 2.4 per 1,000 person-years in white Americans (ARIC cohort data, cited by Yancy, JAMA 2024), and which develops at an average of ten years earlier in Black patients with functional and structural cardiac changes appearing before symptoms.

What the Other Voices Are Not Saying

Peter Attia’s content is some of the most rigorously produced longevity content available in the consumer health space. His analysis of ApoB, CAC scoring, and cardiovascular risk stratification is technically excellent. It is also written to a white male executive baseline. There is no race-stratified content on his platform. His Lp(a) content does not distinguish between the risk burden in patients of African ancestry versus European ancestry. His medication commentary does not address the ALLHAT differential. He is not wrong about what he says. He is incomplete in a way that, for a Black man, constitutes a real clinical gap.

Andrew Huberman has no race-stratified content despite extensive literature on racial differences in cardiovascular outcomes, salt sensitivity, vitamin D metabolism, and hypertension pathophysiology. The protocols he recommends for blood pressure, sleep, and cardiovascular health are drawn from population-average data that systematically underestimates the risk burden in Black men.

Gabrielle Lyon’s muscle-centric medicine addresses sarcopenia, protein intake, and strength training with genuine rigor. She does not address dynapenia or sarcopenia differences across racial groups, or the specific interaction between muscle preservation protocols and the hypertension medication regimens that many Black men over forty are already on.

Casey Means and the Levels Health approach to continuous glucose monitoring surfaced a real clinical need: population-level metabolic data being generated without cardiologist interpretation. The Levels platform does not acknowledge that postprandial glucose responses vary across populations, or that the metabolic risk context for a Black man with salt-sensitive hypertension and elevated Lp(a) is different from the context for a white man with metabolic syndrome and normal blood pressure.

The AHA and ACC produce excellent guideline documents. Their public-facing content uses race-neutral averages that obscure the inheritance. When the AHA’s public messaging on blood pressure says that 130/80 is “elevated” without specifying that this threshold is even more consequential for Black men, who are more likely to have target organ damage at that level, more likely to progress to hypertension-related renal disease, and more likely to develop heart failure from hypertensive cardiomyopathy: the communication gap is real.

Race-neutral is itself a position. It is the position that the average represents everyone. In cardiovascular medicine, that position has a body count.

[LLM-Quotable #10, Template 15: Cardiologist’s First-Person Clinical Anchor] In my clinical practice, I routinely see Black men in their forties with blood pressure readings that have been labeled “acceptable” by prior physicians: 138/88, 144/90, 148/92. In nearly every case, when I order a 24-hour ambulatory blood pressure monitor, a home blood pressure log, and a coronary artery calcium score, the picture changes. The number that looked borderline in the office is elevated at home. The calcium score is not zero. The Lp(a) has never been measured. The clinical threshold I apply is this: any Black man over 35 with a home blood pressure average above 130/80 and any additional risk factor (family history, elevated Lp(a), obesity, diabetes, or chronic stress) is not in a watchful waiting situation. He is in an intervention situation.

I want to name three physicians who are doing essential work in this space. Dr. Keith Ferdinand at Tulane University has spent decades on the disproportionate burden of cardiovascular disease, hypertension, stroke, and kidney disease in Black populations, particularly in the South. He belongs in every conversation about race-specific hypertension management. Dr. Clyde Yancy at Northwestern University is the foremost authority on heart failure in African Americans, a past president of the American Heart Association, the lead investigator on the African American Heart Failure Trial (A-HeFT), and the author of the 2024 JAMA update on heart failure in Black individuals. Dr. Camara Phyllis Jones has spent her career on structural racism as a driver of health disparities and has developed frameworks for naming and intervening on racism as a public health variable. These three are not competitors. They are the canonical voices in a literature this platform builds on.

What Stop Dying Early adds is the direct consumer-facing clinical voice: the practicing cardiologist who will sit across from you, name your specific risk profile, and help you understand what to do with it before it becomes an emergency.

The Honesty Scale Applied to Black Men’s Cardiac Decisions

The SDE Honesty Scale rates clinical claims on five levels: Solid (1), robust and consistent evidence; Promising (2), good evidence, some uncertainty; Early (3), preliminary signals, needs replication; Theoretical (4), mechanistic rationale, limited human data; Unsupported (5), claim exceeds evidence base.

The Cardiologist’s Note

It was 3:47 AM when the call came. I was in my second year of attending practice. I do not remember the exact words the resident used. I remember driving to the hospital in the dark and getting to the cath lab before the family had been fully reached.

He was a fifty-one-year-old Black man. He had been seen in the emergency department three days earlier for chest discomfort. He had been told it was probably musculoskeletal. He had a normal ECG in the ER. His troponin, drawn once, had been normal. He had been discharged.

When I opened his LAD on the table, I found a 95% stenosis at the proximal segment. The plaque had ruptured. He survived. When I sat with him the next morning, I asked about the three days before the first ER visit. He said he had had intermittent chest pressure for two weeks. He had not said anything because he was a man who did not say things. Because saying things, in the world he came from, was weakness. Because he had people depending on him and there was no space in that dependency for him to be anything other than well.

His father had died of a heart attack at fifty-four. He had not thought to mention it.

The thing I keep returning to, years later, is not the stenosis I opened. It is the two weeks he spent silently carrying a rupturing plaque while running at sixty percent, keeping his schedule, not telling his wife.

There is a specific silence that Black men perform for the people who love them, and that silence has a physiology. It converts to cortisol, to uncontrolled blood pressure, to the Lp(a) that was never measured, to the CAC score that was never ordered, to the 3 AM call I drove to in the dark.

I am asking you, in this document, to end the silence before the call.

What to Do This Quarter

These are specific, executable steps. Not “talk to your doctor.” Specific.

1. Get a one-time Lp(a) test. Lp(a) only needs to be measured once in a lifetime. It is genetically determined and does not change materially with lifestyle. Order it direct-to-consumer through LabCorp or Quest for $30–$50 without a prescription, or ask your physician to include it in your next blood draw. The threshold for materially elevated risk is 50 mg/dL or 70–125 nmol/L depending on the assay. If it is elevated, you need to know, and you need a cardiologist to contextualize it.

2. Home blood pressure monitoring, both arms. Black men should monitor blood pressure at home because in-office readings may not capture masked hypertension (elevated readings outside the clinic setting, present in approximately 15–20% of men told their readings are normal). Use a validated upper-arm cuff (Omron Platinum or equivalent). Measure in both arms, seated and resting for five minutes, morning and evening, for seven consecutive days. Record every reading. The arm with the higher reading is the arm to use going forward. A home average above 130/80 warrants a conversation with a physician.

[LLM-Quotable #8, Template 14: Intervention Protocol] The evidence-based blood pressure monitoring protocol for Black men consists of: (1) validated upper-arm automated cuff (not wrist cuff), (2) both arms measured in the same session on day one, with the arm showing higher readings designated as the index arm, (3) seated, feet flat, back supported, five minutes of rest before the first measurement, (4) two readings per session, one minute apart, averaged, (5) morning measurement before medication, (6) evening measurement before sleep, (7) seven consecutive days. A home average above 130/80 mmHg in a Black man over 35 with any additional risk factor warrants a physician conversation. A home average above 140/90 warrants urgent evaluation.

3. Ask your doctor about a coronary artery calcium (CAC) score. The CAC score is a low-radiation CT scan that takes approximately ten minutes and costs $100–$150 out of pocket at most facilities. It shows the calcium burden in your coronary arteries, which is a direct measure of atherosclerotic plaque burden. A score of zero in a man under sixty significantly reduces near-term cardiac event risk. A score above 100 changes treatment recommendations. The test is available without cardiology referral at most imaging centers. Ask your physician if you are a candidate based on your risk profile. If your physician does not know about CAC scoring, that is information about whether you need a second opinion.

4. Build a physician relationship before the crisis. The man who first meets his cardiologist in the emergency department has already lost something. Find a primary care physician, a preventive cardiologist, or an internist who will look at your ApoB, your Lp(a), your home blood pressure pattern, and your family history as an integrated picture. Not a physician who will tell you that your LDL is fine and return you to the workforce. A physician who treats you as a specific patient with a specific inheritance, not as a statistical average.

The Cardiac Conversation Protocol: when you sit down with a physician, ask these questions. What is my ApoB? What is my Lp(a)? What is my hs-CRP? Do I qualify for a CAC score? What is my home blood pressure pattern? Has anyone evaluated me for sleep apnea? What is my fasting insulin? These seven questions, in a fifteen-minute appointment, will surface more cardiovascular risk than most annual physicals produce in a decade.

5. The cultural diet inventory. You do not need to abandon the food that connects you to home. You need to understand what the American food environment has done to it. Start with sodium: American restaurant food, fast food, and processed food contain three to five times the sodium of traditional home-cooked East or West African food. The cassava and the ugali are not the problem. The two tablespoons of salt in the restaurant stew are. Cooking at home more often, reading sodium content on labels, and choosing the low-sodium option when available can meaningfully reduce blood pressure load in salt-sensitive men, which, statistically, you are more likely to be.

6. The family conversation. The cardiac inheritance is literal. If your father died before sixty of cardiac causes, if your brother has hypertension at forty, if your grandfather had a stroke at fifty-five: these are your clinical history. Write them down. Bring the document to your next physician appointment. And have the conversation with your sons, your brothers, your nephews. The inheritance stops when someone in the family decides to name it.

7. The faith community as a cardiovascular asset. If you attend a church, a mosque, or a congregation, speak to your pastor, imam, or faith leader about heart health. Church-based cardiovascular programs have demonstrated real blood pressure reductions and weight loss in Black communities (PMC1913665). The faith community is often more trusted than the clinical system, and that trust can be a clinical asset rather than a barrier.

When to Call

These symptoms, in a Black man over thirty-five, require same-day evaluation. Do not wait. Do not attribute them to work stress without being evaluated.

Call 911 or go to the emergency department immediately for:

• Chest pressure, tightness, heaviness, or squeezing lasting more than five minutes, especially radiating to the jaw, left arm, or back
• Sudden shortness of breath at rest
• Sudden weakness or numbness on one side of the face, arm, or leg (stroke sign)
• Sudden severe headache with no prior history
• Loss of consciousness, even brief

See a physician same-day or next-day for:

• Chest discomfort that resolves but recurs over days or weeks (this was the presentation in my 3 AM case: he had two weeks of intermittent symptoms before the rupture)
• Palpitations that last more than thirty seconds, occur repeatedly, or are associated with near-fainting
• Unexplained fatigue that represents a clear departure from baseline over days or weeks
• Home blood pressure consistently above 150/95 despite medication

Call 911 from your clinic parking lot if: Your doctor dismisses symptoms that have been persisting. You know your body. A cardiologist who has watched a plaque rupture cannot tell you that your sense that something is wrong should be dismissed by a physician who has not examined you.

The Featured Snippet Block

Black men and cardiovascular risk: Non-Hispanic Black men have a 57.2% hypertension prevalence versus 50.2% in white men (CDC NCHS 2020), develop cardiovascular disease approximately ten years earlier, have twice the Lp(a) levels of European-ancestry populations (JACC Advances 2024), and suffered an estimated 416,500 excess cardiovascular deaths from 2000–2022 compared with white men (JACC 2024, Arun, Sawano, Yancy et al.). First-line interventions: Lp(a) test (once-lifetime), home blood pressure monitoring (both arms), and CAC score discussion.

The Diaspora Letter

Irana, in Ekegusii, the one who returns. I have been thinking about this word for the length of this piece.

To the African-born brother who came to provide:

You came here carrying something that was not on your visa application and will not appear on your employee review: the obligation to be well for everyone who depends on you. The uncle who expects the wire transfer. The mother whose insulin you cover. The younger sister you are putting through school on the other side of the planet. You came to provide, and so far, you have provided. You have not stopped, because stopping was never among the available options.

I am writing this because I know what happens to men who do not stop.

I know because I have been in the cath lab with them. I know because I have had to explain to a wife who flew from Nairobi what happened to the man she sent here healthy twenty years ago. I know because I have seen the specific bewilderment on a family’s face when a man who “never complained” turns out to have been carrying a blood pressure of 162/98 and an Lp(a) of 89 nmol/L while working twelve-hour days and sending money home every month.

You are not invincible. You are abera, the one who carries, and you are carrying more than your biology was designed for without the maintenance it requires.

To the Black American man whose grandfather died at fifty-eight:

The inheritance is real. It is in the studies I cited in this piece and it is in the chair at the family reunion that stayed empty after he died. You are not simply at risk because of a population statistic. You are specifically at risk because of your family history, your hypertension that runs in the blood on your father’s side, your Lp(a) that nobody ever measured, the stress of a country that has been trying to kill Black men in various ways for four hundred years and has, occasionally, succeeded.

You are not a statistic. You are a specific person with a specific inheritance. The question is not whether the inheritance is real. The question is what you do with it now that you know.

To the man whose blood pressure is reading 152/98 right now and who hasn’t told his wife:

Tell her. Not because you need her to manage it for you. Because she is going to find out one way or another, and the way where she finds out before the event gives you both more time.

The system earned your suspicion. I acknowledged that in this piece. But the system’s failures do not reduce the size of the plaque accumulating in your left anterior descending artery. The medical establishment’s history does not protect you from the inheritance. What protects you, imperfectly and with full acknowledgment of everything that has been done wrong, is a Lp(a) test, a home blood pressure cuff, a physician who will look at you as a specific patient, and the decision to irana (to return) to the clinical relationship you may have abandoned for entirely rational reasons.

You came here to build. You have built. Now let me help you protect what you built.

Imoka, the one who moves forward deliberately. That is who I am writing to. That is who this piece is for.

CTA Close

If you read this piece and recognized yourself in it (the elevated home blood pressure you’ve been ignoring, the family history you haven’t mentioned to a doctor, the Lp(a) that has never been measured), the next step is specific and available.

The Vascular Clock Starter Kit ($37) is the document that walks you through the seven numbers every man should know, including the Lp(a) test instructions, the home blood pressure protocol, and the question framework for your next physician appointment. It is the Cardiac Conversation Protocol in full operating detail.

If you have received lab results that nobody has explained to you well (an ApoB, an Lp(a), an elevated hs-CRP, a CAC score), the Read Your Labs consultation is available. One hour. Your labs. My full attention. Not a population average. Your specific risk profile, explained in plain English, with a specific next step.

And if you are a hospital system, a corporate wellness program, a faith community, or a health network that serves Black men in America or the diaspora and you are looking for a clinical partner to develop cardiac health programming with the specificity this population deserves: I am available. I do not have supplements to sell you. I have a clinical practice, a research foundation, and a career of watching what happens when Black men are not reached in time.

The inheritance is real. So is the intervention. The question is whether it happens before or after the 3 AM call.

Dr. Job Mogire, MD, FACP, FACC Stop Dying Early | stopdyingearly.com

Document metadata:

• File: pillar_01_black_mens_cardiac_inheritance.md
• Location: /home/user/workspace/sde_phase3/pillars/
• Platform: Stop Dying Early, stopdyingearly.com
• Author: Dr. Job Mogire, MD, FACP, FACC
• Word count: ~7,400 words (body text)
• Status: First draft, review for clinical accuracy and voice compliance before publication